Department of Obstetrics and Gynecology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):620-6. doi: 10.1016/j.jmig.2013.03.012. Epub 2013 May 22.
To evaluate the effect on postoperative pain of intraperitoneal instillation of dilute bupivacaine at the conclusion of laparoscopic hysterectomy.
Prospective, randomized, double-blind, placebo-controlled trial (Canadian Task Force classification I).
Tertiary care, urban, academic teaching hospital.
Women aged 18 to 65 years undergoing total or supracervical laparoscopic hysterectomy with or without salpingo-oophorectomy.
Randomization to intraperitoneal instillation of bupivacaine vs normal saline solution at the conclusion of laparoscopic hysterectomy performed because of benign indications.
A total of 160 patients consented to participate in the study and were randomized to receive either intraperitoneal instillation of 100 mg bupivacaine in 100 mL normal saline solution or 100 mL normal saline solution alone, at the conclusion of laparoscopic hysterectomy. Sixty seven of 77 patients (87%) in the treatment group and 73 of 80 patients (91%) in the placebo group completed the study. There were no significant differences in demographic profile, indication for hysterectomy, or number of previous surgeries between the two groups. All patients were prescribed a standardized routine postoperative analgesic regimen. Pain was measured by patient self-report using a 10-cm visual analog scale (VAS) at 1, 2, 4, 6, 12, and 24 hours postoperatively. Mean VAS scores at all time points were between 2.0 and 4.3 and were highest in the first postoperative hour. VAS scores were not significantly different between the two groups at any time point. None of the measured secondary outcomes were significantly different between the bupivacaine and placebo groups, including total postoperative opioid analgesic use in morphine equivalents (23.2 mg vs 27.5 mg; p = .09), length of hospital stay in hours (23.3 vs 23.0; p = .49), patient satisfaction on a 10-cm VAS (9.0 vs 8.2; p = .12), and complication rates (9% vs 15%; p = .35).
Intraperitoneal instillation of bupivacaine at the conclusion of laparoscopic hysterectomy does not reduce postoperative pain. Opioid analgesic use, length of hospital stay, overall patient satisfaction, and complication rates are also unchanged. Self-reported postoperative pain was low in both groups after this major gynecologic surgery performed laparoscopically.
评估腹腔镜子宫切除术后腹腔内注入稀释布比卡因对术后疼痛的影响。
前瞻性、随机、双盲、安慰剂对照试验(加拿大任务组分类 I)。
三级保健、城市、学术教学医院。
年龄在 18 岁至 65 岁之间,因良性指征接受全子宫切除术或次全子宫切除术,伴或不伴输卵管卵巢切除术。
随机分组,在腹腔镜子宫切除术结束时向腹腔内注入布比卡因或生理盐水。
共有 160 名患者同意参加这项研究,并随机分为两组,一组在腹腔镜子宫切除术后腹腔内注入 100mg 布比卡因加 100ml 生理盐水,另一组仅注入 100ml 生理盐水。治疗组 77 例患者中有 67 例(87%)和安慰剂组 80 例患者中有 73 例(91%)完成了研究。两组患者的人口统计学特征、子宫切除术指征和既往手术次数均无显著差异。所有患者均接受标准化常规术后镇痛方案。疼痛通过患者术后 1、2、4、6、12 和 24 小时的 10cm 视觉模拟评分(VAS)进行自我报告。所有时间点的平均 VAS 评分在 2.0 到 4.3 之间,在术后第一小时最高。两组在任何时间点的 VAS 评分均无显著差异。布比卡因组和安慰剂组的所有次要观察结果均无显著差异,包括吗啡等效物的总术后阿片类镇痛药用量(23.2mg 比 27.5mg;p=0.09)、小时住院时间(23.3 比 23.0;p=0.49)、患者满意度(10cmVAS9.0 比 8.2;p=0.12)和并发症发生率(9%比 15%;p=0.35)。
腹腔镜子宫切除术后腹腔内注入布比卡因不能减轻术后疼痛。阿片类镇痛药的使用、住院时间、总体患者满意度和并发症发生率也没有变化。在进行腹腔镜手术后,两组患者的术后疼痛均较低。